Prof Michael Gnant - Medical University of Vienna, Austria
Benefits of adding bisphosphonates to endrocrine therapy for breast cancer to potentially increase anti-tumour efficacy. Denosumab vs Zoledronate. Interviewed by an expert from the European Institute of Oncology at San Antonio Breast Cancer Symposium 2009.